All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Chronic graft-versus-host disease (cGvHD) remains a major cause of high non-relapse mortality and morbidity rates after allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Corticosteroids are the currently used standard of care for patients with cGvHD. Previous data suggests that cGvHD may associated with germinal center (GC) reaction, in which T follicular helper cells and germinal center B-cells increase and start to produce antibodies to induce cGvHD. As a consequence, targeting GCs may be a feasible therapy option for patients with cGvHD.
BCL6 is a master transcription factor which supports the differentiation of naive helper T cells in follicular helper T cells and assists GC development with chromatin-associated factors such as the EZH2 lysine methyltransferase or the BRD4 epigenetic reader protein.
Katelyn Paz from the University of Minnesota, Minneapolis, MN, USA, and colleagues evaluated BCL6 expression in both donor T cells and B cells and their role in cGvHD development. The study group utilized a small-molecule, peptidomemidic BCL6 inhibitor, 79-6, for the treatment of cGvHD in a murine model. B6→B10.BR (BO cGvHD) and B10.D2Balb/c (scleroderma cGvHD) models were used.
In summary, the study group stated that BCL6 expression is essential in donor marrow B and T cells to induce germinal center reaction in chronic GvHD mice. A small-molecule inhibitor of BCL6, 79-6, was found to be efficient for the treatment of mice cGvHD. The authors added that “targeting BCL6 represents a new approach with specificity for a master GC regulator that would extend the currently available second-line agents.”
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox